A Phase 4, Randomized, Double-Blind, 2-Way Crossover Study of Continuous Subcutaneous Insulin Infusion (CSII) With, Compared to Without, Pretreatment With Recombinant Human Hyaluronidase (rHuPH20).
Phase of Trial: Phase IV
Latest Information Update: 01 Oct 2014
At a glance
- Drugs Hyaluronidase (Primary) ; Insulin
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Halozyme Therapeutics
- 28 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Jul 2013 Planned End Date changed from 1 May 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov.
- 11 Jul 2013 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.